• Vor Biopharma posted a net loss of $219.6 million in first-quarter 2026, worsening from a $32.5 million loss a year earlier.
• R&D expense fell 34.08% to $17.6 million, while G&A expense more than doubled to $17.6 million.
• Cash, cash equivalents and marketable securities totaled $491.5 million as of March 31, 2026, with runway projected into early 2029.
• Enrollment remained on track in Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis, with topline data expected in 1H27.
• Phase 3 UPSTREAM SjD trial of telitacicept in primary Sjögren's disease continued enrolling, with CEO Jean-Paul Kress citing clinician feedback pointing to a shift toward upstream B-cell modulation for broader, more durable control.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vor Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605130830PRIMZONEFULLFEED9719382) on May 13, 2026, and is solely responsible for the information contained therein.